Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function
- PMID: 17134622
- DOI: 10.1016/j.amjcard.2006.06.023
Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function
Abstract
Several emerging cardiac markers constitute strong predictors among patients with coronary artery disease. In particular, brain natriuretic peptide (BNP), troponin T (TnT), and C-reactive protein (CRP) are related to increased risk of recurrent ischemic events and death. However, little is known about the utility of these biomarkers in combination. This study examined risk assessment in patients with coronary artery disease and preserved systolic function. We studied 208 consecutive patients (138 men, 70 women) with stable angina, unstable angina, and non-Q-wave myocardial infarction whose plasma BNP, TnT, and CRP levels were measured at hospital admission. All recruited patients underwent echocardiographic examination, and selective coronary angiography was performed. After adjusting for clinical presentation, age, gender, and common risk factors, BNP was demonstrated as a strong predictor of heart failure (6 months, odds ratio [OR] 2.03, 95% confidence interval [CI] 1.24 to 2.9, p <0.01; 12 months, OR 2.65, 95% CI 1.69 to 3.5, p <0.001) and mortality at 3, 6, and 12 months (p <0.001). BNP was also significantly related to extent of coronary artery disease and left anterior descending artery involvement (p <0.01). Patients with a BNP level >80 pg/ml in all 3 groups had a significantly poorer prognosis with increased incidence of heart failure and death. CRP was related to recurrent ischemic events (infarct or recurrent angina, OR 1.4, 95% CI 1.14 to 2.08, p <0.01) and was associated with major cardiac revascularization at 12 months (OR 1.51, 95% CI 1.29 to 1.73, p <0.001). TnT demonstrated a mild correlation with recurrent infarct or angina at 12 months (OR 1.1, 95% CI 0.96 to 1.22, p <0.05) but appeared related to multivessel coronary artery disease (OR 1.47, 95% CI 1.05 to 1.99, p <0.01). In conclusion, BNP appears to be associated with a long-term increased risk of mortality and heart failure in patients with apparently mild risk. BNP is also associated with a larger extent and greater severity of myocardial ischemia. Early BNP measurement could provide incremental information to TnT and CRP, and it may be the strongest independent predictor of cardiac outcome in subjects without left ventricular dysfunction or enlargement.
Similar articles
-
Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries.Am J Cardiol. 2005 Dec 15;96(12):1705-10. doi: 10.1016/j.amjcard.2005.07.094. Epub 2005 Nov 2. Am J Cardiol. 2005. PMID: 16360361
-
B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function.Eur J Prev Cardiol. 2012 Jun;19(3):366-73. doi: 10.1177/1741826711406608. Epub 2011 Apr 4. Eur J Prev Cardiol. 2012. PMID: 21464097
-
Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Am J Cardiol. 2010 Apr 15;105(8):1065-9. doi: 10.1016/j.amjcard.2009.12.003. Epub 2010 Feb 20. Am J Cardiol. 2010. PMID: 20381654 Clinical Trial.
-
[Natriuretic peptides and multimarker approach to risk stratification of patients with acute coronary syndromes].Med Pregl. 2006 May-Jun;59(5-6):248-52. doi: 10.2298/mpns0606248m. Med Pregl. 2006. PMID: 17039908 Review. Serbian.
-
Natriuretic peptides in coronary disease with non-ST elevation: new tools ready for clinical application?Recent Pat Cardiovasc Drug Discov. 2007 Jan;2(1):1-4. doi: 10.2174/157489007779606185. Recent Pat Cardiovasc Drug Discov. 2007. PMID: 18221096 Review.
Cited by
-
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.Vasc Health Risk Manag. 2010 Jun 1;6:411-8. doi: 10.2147/vhrm.s5789. Vasc Health Risk Manag. 2010. PMID: 20539843 Free PMC article. Review.
-
Natriuretic peptides in heart failure: where we are, where we are going.Intern Emerg Med. 2011 Feb;6(1):63-8. doi: 10.1007/s11739-010-0438-x. Epub 2010 Sep 18. Intern Emerg Med. 2011. PMID: 20853071 Review.
-
B-type natriuretic peptide release and left ventricular filling pressure assessed by echocardiographic study after subarachnoid hemorrhage: a prospective study in non-cardiac patients.Crit Care. 2009;13(3):R76. doi: 10.1186/cc7891. Epub 2009 May 20. Crit Care. 2009. PMID: 19454040 Free PMC article.
-
Transient elevation of NT-pro-BNP as a predictor for myocardial ischemia.Clin Res Cardiol. 2010 Dec;99(12):857-9. doi: 10.1007/s00392-010-0211-1. Epub 2010 Sep 7. Clin Res Cardiol. 2010. PMID: 20821018 No abstract available.
-
B-type natriuretic peptide as a predictor of anterior wall location in patients with non-ST-elevation myocardial infarction.Clinics (Sao Paulo). 2011;66(3):437-41. doi: 10.1590/s1807-59322011000300013. Clinics (Sao Paulo). 2011. PMID: 21552669 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous